Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules
23U-0160
Phase 2 small_molecule active
Quick answer
Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules for Diffuse Midline Glioma, H3K27-altered is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Diffuse Midline Glioma, H3K27-altered
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active